NClip

Gonadotropin-Releasing Hormone Analogs

3 min read

Gonadotropin-Releasing Hormone Analogs

Key Points

  • GnRH analogs initially stimulate then suppress pituitary gonadotropin (FSH and LH) release, creating a medical menopause or castration state.
  • Used for endometriosis, uterine fibroids, precocious puberty, and hormone-sensitive cancers.
  • In transgender feminizing pathways, GnRH analogs can reduce testosterone and may reduce the required estrogen dose or spironolactone burden.
  • Common agents include leuprolide, goserelin, and nafarelin.
  • Long-term use causes estrogen/androgen depletion effects including bone-density loss and menopausal symptoms.
  • In metastatic prostate-cancer pathways, GnRH analogs are commonly combined with antiandrogens such as bicalutamide.

Mechanism of Action

GnRH agonists initially stimulate pituitary FSH and LH release (flare effect) before causing receptor downregulation and desensitization. After 2 to 4 weeks of continuous administration, gonadotropin secretion is profoundly suppressed, leading to marked reduction in estrogen or testosterone production. GnRH antagonists (ganirelix, cetrorelix) block GnRH receptors directly without the initial flare.

Indications

  • Endometriosis (pain reduction and lesion regression).
  • Uterine fibroids (preoperative shrinkage).
  • Precocious puberty (halting premature sexual development).
  • Advanced prostate cancer (androgen deprivation).
  • Assisted reproductive technology protocols (ovulation timing control).
  • Selected transgender feminizing regimens when androgen suppression requires alternatives to spironolactone.

Nursing Considerations

  • Monitor for initial symptom flare during the first 2 to 4 weeks of GnRH agonist therapy (worsening pain in endometriosis, bone pain in prostate cancer).
  • Assess bone mineral density with DEXA scan for clients on long-term therapy; bone-density loss is a significant concern.
  • Monitor menopausal symptoms in female clients: hot flashes, vaginal dryness, mood changes.
  • Monitor testosterone levels in male clients on androgen deprivation.
  • In transgender regimens, counsel that repeated injections or multiple daily intranasal dosing plus cost/insurance barriers may limit use.
  • In prostate-cancer pathways, coordinate concurrent antiandrogen therapy during androgen-deprivation plans when ordered.
  • Ensure proper injection technique for depot formulations (subcutaneous or intramuscular).
  • Duration of therapy is often limited to 6 months for endometriosis due to bone-density loss; add-back therapy with low-dose estrogen/progestin may be prescribed.
  • Explain reversibility expectations: discontinuation typically allows return of sex characteristics associated with sex assigned at birth.

Side Effects and Adverse Effects

  • Common: Hot flashes, sweating, headache, mood changes, decreased libido.
  • Female-specific: Vaginal dryness, breakthrough bleeding, breast tenderness.
  • Male-specific: Erectile dysfunction, gynecomastia, testicular atrophy.
  • Musculoskeletal: Bone-density loss with prolonged use.
  • Initial flare: Temporary worsening of symptoms in first 2 to 4 weeks.

Health Teaching

  • Expect an initial flare of symptoms before improvement begins.
  • Report severe bone pain, worsening symptoms, or difficulty urinating.
  • Use non-hormonal contraception during therapy because ovulation may still occur initially.
  • Calcium and vitamin D supplementation may be recommended to support bone health.
  • Adhere to scheduled injection appointments for depot formulations.

Self-Check

  1. Why do GnRH agonists cause an initial symptom flare before achieving suppression?
  2. What long-term adverse effect limits the duration of GnRH analog therapy for endometriosis?
  3. How do GnRH agonists differ from GnRH antagonists in their mechanism?

Graph View